Unlock Therapeutic Potential: A Deep Dive into TGF-β Receptor I Inhibitor CAS 356559-20-1
Explore the cutting-edge pharmaceutical intermediate, CAS 356559-20-1, a potent and selective TGF-β Receptor I (ALK5) inhibitor. Discover its crucial role in research and potential treatments for fibrosis, cancer, and pulmonary arterial hypertension. Learn about its applications and why we are a trusted supplier in China.
Get a Quote & SampleProduct Core Value
![6-[2-tert-Butyl-5-(6-methyl-pyridin-2-yl)-1H-imidazol-4-yl]-quinoxaline](https://www.nbinno.com/webimg/gemini_6892a6ed56d02_1754441453.png)
6-[2-tert-Butyl-5-(6-methyl-pyridin-2-yl)-1H-imidazol-4-yl]-quinoxaline
This advanced pharmaceutical intermediate, known for its CAS number 356559-20-1, stands out as a highly selective inhibitor of the TGF-β Receptor I (ALK5) kinase. With an IC50 of 14.3 nM, it effectively blocks TGF-β1-induced phosphorylation and nuclear translocation of Smad2/3, making it a valuable tool in understanding and combating fibrotic diseases. As a leading manufacturer in China, we provide this high-quality compound for your research needs.
- Research into TGF-beta Signaling Pathway Inhibitors: This compound is pivotal for studies targeting the TGF-beta signaling pathway, a key regulator of cellular processes.
- Potential Treatments for Pulmonary Arterial Hypertension: In vivo studies demonstrate its efficacy in reversing pulmonary arterial pressure and inhibiting right ventricular hypertrophy, offering hope for PAH patients.
- Anti-fibrotic Drug Development Applications: Its ability to attenuate fibrotic alterations in lung tissue and inhibit key fibrosis markers positions it as a promising candidate for anti-fibrotic therapies.
- Modulating Carcinogenesis and Tumor Development: Evidence suggests efficacy in suppressing the development of uterine mesenchymal tumors, highlighting its potential in cancer research.
Key Advantages of Our Product
High Selectivity and Potency
As a potent and selective TGF-β Receptor I inhibitor, our product offers precise targeting for research, minimizing off-target effects critical for effective pharmaceutical intermediate research.
Proven In Vivo Efficacy
Demonstrated success in animal models for renal fibrosis and pulmonary fibrosis showcases its real-world applicability in combating fibrotic diseases, making it a crucial component for anti-fibrotic drug development.
Broad Therapeutic Potential
Its ability to address conditions like pulmonary arterial hypertension and its impact on mesenchymal tumors suggest a wide range of therapeutic possibilities, supporting targeted cancer therapies.
Key Applications
Fibrosis Research
Essential for studying fibrotic mechanisms and evaluating potential treatments for conditions like kidney fibrosis and pulmonary fibrosis, aligning with goals of anti-fibrotic drug development.
Cancer Therapeutics Development
Investigating its role in inhibiting tumor development and proliferation, particularly in mesenchymal tumors, contributes to advancements in targeted cancer therapies.
Pulmonary Hypertension Treatment Studies
Critical for research into novel treatments for pulmonary arterial hypertension (PAH), by reversing pulmonary arterial pressure and inhibiting cardiac remodeling, supporting pulmonary hypertension treatments.
TGF-beta Signaling Pathway Analysis
A vital tool for researchers dissecting the complexities of the TGF-beta signaling pathway, crucial for understanding various cellular processes and disease states, underscoring its value in TGF-beta signaling pathway inhibitors research.